Pain management最新文献_第3页

Risk factors affecting the therapeutic effect of onabotulinum toxin a on chronic migraine. 影响肉毒杆菌毒素a治疗慢性偏头痛疗效的危险因素。

IF 1.4

Pain management Pub Date : 2025-02-01 Epub Date: 2025-01-27 DOI: 10.1080/17581869.2025.2458448

Leonor Mendes-Andrade, Inês Mendes-Andrade, Beatriz Medeiros, Madalena Pinto, Andreia Costa

{"title":"Risk factors affecting the therapeutic effect of onabotulinum toxin a on chronic migraine.","authors":"Leonor Mendes-Andrade, Inês Mendes-Andrade, Beatriz Medeiros, Madalena Pinto, Andreia Costa","doi":"10.1080/17581869.2025.2458448","DOIUrl":"10.1080/17581869.2025.2458448","url":null,"abstract":"Background: OnabotulinumtoxinA demonstrates effectiveness in chronic migraine prevention but is hindered by variable patient responses. This study aims to identify modifiable and non-modifiable risk factors influencing the response to onabotulinumtoxinA.Methods: We conducted a retrospective cohort study at a tertiary hospital involving chronic migraine patients treated with onabotulinumtoxinA. Data on risk factors and patient perceptions were collected through medical records and questionnaires.Results: A total of 131 patients were included. At 12 months, a significant reduction in headache frequency was observed: from 26 episodes pre-treatment to 13 at 3 months, 12 at 6 months, 11 at 9 months, and 10 at 12 months. A third of patients stopped overusing medication after treatment. Univariate logistic regressions revealed that fibromyalgia was associated with a reduced likelihood of achieving ≥50% response to onabotulinumtoxinA (OR (odds ratio) = 0.213, p = 0.031), while secondary education was associated with an increased likelihood of response (OR = 4.400, p = 0.029). Adjusted logistic regression confirmed that fibromyalgia significantly reduced the likelihood of ≥50% response (aOR (adjusted odds ratio) = 0.064, p = 0.033).Conclusions: This study confirms the real-world effectiveness of onabotulinumtoxinA in reducing headache frequency. Furthermore, patients with fibromyalgia may have a diminished likelihood of responding positively, underscoring the importance of personalized treatment strategies.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"65-71"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864016/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intranasal overdose reversal formulations: a rapid review of available agents. 鼻内过量逆转制剂：对现有药物的快速回顾。

IF 1.4

Pain management Pub Date : 2025-02-01 Epub Date: 2025-02-04 DOI: 10.1080/17581869.2025.2461445

Kimberly Bernosky-Smith, Orian Painter, Seth Butler, Dipesh Patel, Brian Clemency, Joshua Lynch

{"title":"Intranasal overdose reversal formulations: a rapid review of available agents.","authors":"Kimberly Bernosky-Smith, Orian Painter, Seth Butler, Dipesh Patel, Brian Clemency, Joshua Lynch","doi":"10.1080/17581869.2025.2461445","DOIUrl":"10.1080/17581869.2025.2461445","url":null,"abstract":"The opioid epidemic continues to pose a significant threat to public health. Naloxone, a potent opioid antagonist, has proven to be a crucial tool in reversing opioid overdoses. Efforts to increase access to overdose reversal agents, initially given by injection in hospitals and emergency environments, resulted in the development of intranasal (IN) forms of naloxone, and more recently, nalmefene. This rapid review examines the currently available IN overdose reversal agents in the United States, focusing on their dosing, efficacy, and prescription status.We conducted a comprehensive search of the FDA Electronic Drug and Listing System (eDRLS) to identify all approved naloxone and nalmefene formulations in 2024. The search yielded nine available overdose reversal agents, including generic formulations of naloxone available over the counter and accessible to the public. Additionally, newer agents, such as nalmefene, offer longer-acting effects and may provide additional benefits in certain overdose scenarios.As the opioid crisis evolves, it is essential to stay informed about the latest advancements in formulations of reversal agents. By understanding the characteristics and availability status of available agents, health care providers, public health officials, and individuals can make informed decisions about the most appropriate overdose treatment strategies.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"105-113"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11853544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic role of Differential Target Multiplexed (DTM) spinal cord stimulation in painful diabetic neuropathy. Case report. 差异靶多路（DTM）脊髓刺激在疼痛性糖尿病神经病变中的治疗作用。病例报告。

IF 1.4

Pain management Pub Date : 2025-01-01 Epub Date: 2024-12-20 DOI: 10.1080/17581869.2024.2444250

Roberto Gazzeri, Felice Occhigrossi, Matteo Luigi Giuseppe Leoni, Mariangela Martino, Riccardo Schiaffini

{"title":"Therapeutic role of Differential Target Multiplexed (DTM) spinal cord stimulation in painful diabetic neuropathy. Case report.","authors":"Roberto Gazzeri, Felice Occhigrossi, Matteo Luigi Giuseppe Leoni, Mariangela Martino, Riccardo Schiaffini","doi":"10.1080/17581869.2024.2444250","DOIUrl":"10.1080/17581869.2024.2444250","url":null,"abstract":"Diabetic peripheral polyneuropathy (DPN) is the most common cause for diabetic foot complications, including diabetic ulcers, Charcot arthropathy, and lower limb amputations. Spinal Cord Stimulation (SCS) is a safe and effective treatment used for pain reduction in neuropathic/nociceptive pain conditions; the most common stimulation modalities used for the management of painful diabetic neuropathy were conventional paresthesia-based and high-frequency SCS, which stimulate the A beta fibers in the dorsal column of the spinal cord. Differential Target Multiplexed (DTM) SCS is a novel paresthesia-free stimulation technique targeting the supportive glial cells in the nervous system, modulating glial cells and neurons with a rebalance of their interactions. We report a case of severe painful DPN who had immediate pain relief after DTM-SCS implantation, with constant pain relief during the 12 months follow-up. We also investigated the effect of neurostimulation on diabetes control, evaluating the preoperative and postoperative glucose metrics using Continuous Glucose Monitoring (CGM) and compared neurophysiological examination results of the peripheral lower limbs' nerves.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"15-19"},"PeriodicalIF":1.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11801338/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world healthcare utilization and costs of peripheral nerve stimulation with a micro-IPG system. 现实世界的医疗保健利用和成本的周围神经刺激与微ipg系统。

IF 1.4

Pain management Pub Date : 2025-01-01 Epub Date: 2025-01-06 DOI: 10.1080/17581869.2025.2449810

Hemant Kalia, Bishnu Thapa, Peter Staats, Patrick Martin, Kori Stetter, Becca Feldman, Carl Marci

{"title":"Real-world healthcare utilization and costs of peripheral nerve stimulation with a micro-IPG system.","authors":"Hemant Kalia, Bishnu Thapa, Peter Staats, Patrick Martin, Kori Stetter, Becca Feldman, Carl Marci","doi":"10.1080/17581869.2025.2449810","DOIUrl":"10.1080/17581869.2025.2449810","url":null,"abstract":"Aim: To characterize real-world healthcare resource utilization (HCRU) and costs in adults with chronic pain of peripheral nerve origin treated with peripheral nerve stimulation (PNS) using the micro-implantable pulse generator (IPG).Materials & methods: This retrospective observational study (9/1/19-1/31/23) linked patients from the Nalu medical database to the OM1 Real-World Data Cloud (RWDC). Eligible patients received the micro-IPG implant for PNS, were identifiable in both databases, and had ≥ 12 months of RWDC pre/post-implantation claims data. Primary outcomes were all-cause HRCU and medical costs (12 months pre- and post-implantation); secondary outcomes were all-cause pharmacy costs, including opioids, over the same time.Results: Patients (N = 122) had a higher mean (standard deviation; SD) number of outpatient visits pre-implantation (5.7 [5.4]) than post-implantation (4.9 [5.7]). Mean (SD) total medical costs were 50% lower, from $27,493 ($44,756) to $13,717 ($23,278). Median (first-third quartile [Q1-Q3]) medical costs were 57% lower, from $11,809 ($4,075-$31,788) to $5,094 ($1,815-$13,820). Mean (SD) pharmacy costs (n = 77) were higher post-implantation ($22,470 [$77,203]) than pre-implantation ($20,092 [$64,132]), while median (Q1-Q3) costs were lower (from $2,708 [$222 -11,882] to $2,122 [$50-9,370]). Post-implantation, the proportion of patients using opioids was 31.4% lower.Conclusion: Patients with PNS using the micro-IPG had reduced HCRU, costs, and opioid use.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"27-36"},"PeriodicalIF":1.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11801342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Supporting youth who have chronic pain and their caregivers through creative healing for youth in pain (CHYP). 通过创造性治疗疼痛青年（CHYP），支持患有慢性疼痛的青年及其照顾者。

IF 1.4

Pain management Pub Date : 2025-01-01 Epub Date: 2024-12-23 DOI: 10.1080/17581869.2024.2444860

Megan Sweeney, Kimberly Poston Miller, Lonnie Zeltzer

引用次数: 0

Real-world long-term outcomes of peripheral nerve stimulation: a prospective observational study. 周围神经刺激的现实世界长期结果：一项前瞻性观察研究。

IF 1.4

Pain management Pub Date : 2025-01-01 Epub Date: 2025-01-21 DOI: 10.1080/17581869.2025.2451605

Darwin Luna, Gabrielle Hettie, Luke Pirrotta, Vafi Salmasi, Jennifer M Hah

{"title":"Real-world long-term outcomes of peripheral nerve stimulation: a prospective observational study.","authors":"Darwin Luna, Gabrielle Hettie, Luke Pirrotta, Vafi Salmasi, Jennifer M Hah","doi":"10.1080/17581869.2025.2451605","DOIUrl":"10.1080/17581869.2025.2451605","url":null,"abstract":"Aim: We aimed to evaluate real-world outcomes of peripheral nerve stimulation (PNS) used to treat chronic neuropathic pain (CNP) at a tertiary pain management center.Methods: Thirty adults who underwent PNS for CNP between June 2015 and September 2021 completed pain and psychosocial assessments in the 6 months before, and 2-3 years after PNS treatment. Pain intensity was measured using the NIH Patient Reported Outcomes Measurement Information System (PROMIS) Pain Intensity Short From (3A). Psychosocial outcomes including depression, anxiety, and sleep disturbance were also measured.Results: Prior to receiving PNS, long-term responders reported significantly fewer depressive symptoms compared to non-responders (PROMIS depression t-score 50.3 [10.7] vs 57.9 [8.9]; p-value = 0.05). Eleven participants (36.7%) reported long-term treatment response. There was a significantly greater improvement in pain intensity among responders compared to non-responders who reported increased pain (PROMIS Pain Intensity score -9.0 [-4.2] vs. +3.1[+3.2]; p-value < 0.0001).Conclusions: Patients report clinically meaningful long-term pain relief after receiving PNS through both 60-day and permanent implant systems, with significant reductions in pain intensity observed in long-term responders. Long-term responders reported fewer depressive symptoms compared to non-responders prior to receiving therapy, emphasizing the importance of psychological screening and psychological optimization prior to receiving PNS.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"37-44"},"PeriodicalIF":1.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11801347/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Peripheral magnetic stimulation for the treatment of fibromyalgia: a systematic review and meta-analysis. 外周磁刺激治疗纤维肌痛：系统回顾和荟萃分析。

IF 1.4

Pain management Pub Date : 2025-01-01 Epub Date: 2025-01-30 DOI: 10.1080/17581869.2025.2459594

Alvin Leenus, Rayaan Rahman, Elad Dana, Cody Tran, Duncan Westwood, Evgeny E Osokin, Yasmine Hoydonckx, Massieh Moayedi, Salman Hirani, James S Khan

{"title":"Peripheral magnetic stimulation for the treatment of fibromyalgia: a systematic review and meta-analysis.","authors":"Alvin Leenus, Rayaan Rahman, Elad Dana, Cody Tran, Duncan Westwood, Evgeny E Osokin, Yasmine Hoydonckx, Massieh Moayedi, Salman Hirani, James S Khan","doi":"10.1080/17581869.2025.2459594","DOIUrl":"10.1080/17581869.2025.2459594","url":null,"abstract":"Objectives: To systematically review and conduct a meta-analysis of studies on peripheral magnetic stimulation (PMS) for fibromyalgia (FM) treatment.Methods: MEDLINE, EMBASE, CENTRAL, CINHAL, Web of Science, and ProQuest databases were searched from inception to July 2023 for studies in adult patients with FM treated with PMS. Studies using transcranial magnetic stimulation were excluded.Results: Six randomized controlled trials (RCTs) (n = 279 patients) were identified and included in the review. PMS regimens varied, ranging from 8 to 40 min per session over 3-84 days. All studies compared PMS to a visually and physically identical sham device without magnetic fields. Most of the included studies demonstrated positive findings for PMS on pain and functional outcomes. In our meta-analysis, PMS significantly reduced pain scores within 1-3 months (mean difference -1.86 on NRS, 95% confidence interval -2.85 to -0.87, p = 0.0002, I2 = 68%, 4 studies [154 participants], low quality of evidence), but not at ≥3 months (low quality of evidence). Minimal adverse effects were reported.Discussion: Evidence for PMS use in FM is encouraging for short-term benefit. However, heterogeneous patient populations, varied PMS regimens, and limited number of studies are important limitations. Large, high-quality RCTs are needed to confirm PMS benefits and to make definitive recommendations.Protocol registration: PROSPERO Identifier is CRD42021235164.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"45-53"},"PeriodicalIF":1.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11801343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143067186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plain language summary: Phase 3 study of a pain medication (liposomal bupivacaine) for pain relief after foot surgery. 简单的语言总结：一种用于足部手术后疼痛缓解的止痛药（布比卡因脂质体）的3期研究。

IF 1.4

Pain management Pub Date : 2025-01-01 Epub Date: 2025-02-02 DOI: 10.1080/17581869.2025.2459052

Gary Schwartz, Jeffrey Gonzales, O'Dane Brady

引用次数: 0

The effect of oral methadone on the QTc interval in cancer pain patients. 口服美沙酮对癌痛患者QTc间期的影响。

IF 1.4

Pain management Pub Date : 2025-01-01 Epub Date: 2025-01-22 DOI: 10.1080/17581869.2025.2457316

Soun Sheen, Joy Choo, Billy Huh, Matthew Chung

{"title":"The effect of oral methadone on the QTc interval in cancer pain patients.","authors":"Soun Sheen, Joy Choo, Billy Huh, Matthew Chung","doi":"10.1080/17581869.2025.2457316","DOIUrl":"10.1080/17581869.2025.2457316","url":null,"abstract":"Introduction: The QTc prolongation effect of methadone has been extensively studied at higher doses commonly used in opioid dependence maintenance therapy, but evidence remains limited regarding its impact at the lower doses typically prescribed for cancer pain. This study aims to evaluate the effect of oral methadone on QTc intervals in cancer pain patients.Methods: A retrospective analysis was performed on adult patients initiated on oral methadone therapy for cancer. Pre- and post-methadone QTc intervals, obtained within six months before and between six to twelve months after methadone initiation, respectively, were compared. The proportion of patients with QTc intervals greater than 450 msec and 500 msec before and after methadone therapy were compared.Results: Among the total of 310 patients, the mean pre-methadone QTc was 384.5 ± 37.8 msec (95% CI 380.3, 388.7) and the mean post-methadone QTc was 388.5 ± 43.4 msec (95% CI 383.6, 393.3). No statistically significant difference in QTc interval was observed (p = 0.1). The proportion of patients with a QTc greater than 450 msec and 500 msec pre- and post-methadone were also not statistically different.Conclusion: Lower doses of oral methadone for cancer pain do not result in significant QTc prolongation.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"21-25"},"PeriodicalIF":1.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11801344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143024401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel non-opioid analgesics in pain management. 新型非阿片类镇痛药在疼痛治疗中的应用。

IF 1.4

Pain management Pub Date : 2024-12-01 Epub Date: 2024-12-18 DOI: 10.1080/17581869.2024.2442292

Tariq G Pulskamp, Lucy M Johnson, Daniel J Berlau

{"title":"Novel non-opioid analgesics in pain management.","authors":"Tariq G Pulskamp, Lucy M Johnson, Daniel J Berlau","doi":"10.1080/17581869.2024.2442292","DOIUrl":"10.1080/17581869.2024.2442292","url":null,"abstract":"Effective pain management has long been hindered by the limitations and risks associated with opioid analgesics, necessitating the exploration of novel, non-opioid alternatives. A comprehensive literature search was conducted using PubMed and Google Scholar during October and November 2024 to identify studies on emerging non-opioid pain management therapeutics. This review evaluates three promising classes of mechanism-specific therapeutics: nerve growth factor (NGF) monoclonal antibodies, transient receptor potential vanilloid 1 (TRPV1) antagonists, and selective sodium channel blockers. By targeting distinct pathways involved in pain sensation, these therapies aim to provide relief for various pain types, including chronic, inflammatory, and neuropathic pain, with potentially fewer side effects. Through a detailed analysis of their mechanisms of action and current evidence, this review highlights the clinical potential of each class, addressing both their efficacy and safety challenges. Ultimately, these emerging therapies represent significant advancements in non-opioid pain management, with the potential to reshape standard approaches to patient care.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"641-651"},"PeriodicalIF":1.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11702995/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0